Chapman 2004.

Study characteristics
Methods	RCT
Participants	N = 54 (29F/25M) Probable AD, on stable dose of donepezil for at least 3 months Mean MMSE 20.87 (SD 3.55, range 12‐28) Age 76.4 (SD 7.9; range 54‐91) Living at home initially
Interventions	Cognitive stimulation + donepezil Donepezil only
Outcomes	Cognition: MMSE; ADAS‐Cog ADL: Texas Functional Living Scale Behavioural problems: NPI ‐ Irritability and Apathy Quality of Life: QoL‐AD Global functioning: CBIC Verbalisation: Composite discourse score Carer distress ‐ derived from the NPI 10‐month follow‐up data available
Notes	90 minutes, once a week, for 8 weeks
Risk of bias
Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Low risk	Remote telephone randomisation, using a SAS procedure
Allocation concealment (selection bias)	Low risk	Independent randomisation procedure
Blinding of outcome assessment (detection bias) All outcomes	Low risk	All raters underwent extensive training; assessors blinded to group allocation
Incomplete outcome data (attrition bias) All outcomes	Low risk	Intention‐to‐treat analysis used. 24% attrition rate at end of study
Selective reporting (reporting bias)	Low risk	Data on all measures reported
Other bias ‐ training and supervision	Low risk	Programme led by trained speech therapist, assisted by three Master’s level speech language pathology students, who underwent a 2‐hr training session before beginning treatment of each group and were provided with written reference materials. Weekly meetings were held in order to ensure the programme was implemented as designed.
Other bias ‐ treatment manual	Low risk	No indication of a manual, but a clear structure to follow was evident.